+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cell Line Development and Characterization Services by Sources of Cell Lines/Expression Systems, Applications of Cell Lines, and Geography: Industry Trends and Global Forecasts, 2020-2030

  • PDF Icon

    Report

  • 483 Pages
  • January 2021
  • Region: Global
  • Roots Analysis
  • ID: 5240731
Description Jump to:

Overview

Over the years, the biopharmaceutical market has grown into a promising, high value vertical within the overall pharmaceutical industry. In fact, nearly 29% and 25% of the total number of novel drugs approved by the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) in 2018 and 2019, respectively, were biologics. As a result, the pipeline of biologics and biosimilars is growing at a commendable pace. Given that the development and manufacturing of such therapies require living biological systems, there has been a surge in demand for different types of cell lines. In fact, around 84% of the therapeutic proteins marketed in the last five years, were produced using various mammalian and microbial cells. A recent study revealed that over 30,000 research articles published in 33,000 journals featured data generated from experiments that used misidentified or contaminated cell lines. This is a genuine concern in the field of medical research, which is becoming increasingly dependent on cell-based assays and experimentation. Therefore, in modern medical research, proper cell line characterization is a necessity in order to preserve the authenticity and accuracy of experimental research.

Given the cost intensive nature of pharmacological R&D, medical researchers/drug developers are consistently on the lookout for ways to optimize operational efficiencies, as well as reduce affiliated costs; in this context, outsourcing has emerged as a preferred business model. Presently, there are several contact service providers that claim to have the necessary expertise to develop and characterize cell lines. The technical aspect of this field is also witnessing a lot of innovation, especially with regard to automating various steps of the cell line development process. New genome editing technologies, such as the CRISPR/Cas-9, are also being extensively used to improve the quality of recombinant cell lines. Unlike drug developers, the capabilities of service providers are usually more focused to their respective service portfolios. Moreover, such companies ensure that they have the latest upgrades in equipment and infrastructure, in order to improve the quality of services offered. In fact, in the recent past, a number of service providers offering cell lines-related services, have forged strategic alliances with and/or acquired other players, in order to further enhance their respective portfolios. Considering the growing trend of outsourcing and the ongoing efforts of service providers to improve/expand their offerings, we believe the contract services market for cell line development and characterization is likely to evolve at a steady pace, till 2030.

Scope of the Report

The “Cell Line Development and Characterization Services Market (2nd Edition), 2020-2030” report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution in this industry, over the next ten years. The study underlines an in-depth analysis of the services offered for the development and characterization of cell lines, which are intended for use in various R&D and/or therapeutic purposes. 

In addition to other elements, it includes:


  • A detailed review of the overall landscape of the cell line development services market, highlighting the contributions of contract service providers, along with the information on year of establishment, company size, location of headquarters, sources of cell lines and expression systems offered (mammalian, microbial, insect and avian), integrated cell line characterization, biosimilar cell line development and gene editing cell line development services offered, gene delivery method used (physical, chemical, biological and non-biological), type of gene expression (stable and transient), usage of serum-free/animal component free cell culture media, types of cell cultures (suspension and mixed growth properties), types of cells offered (recombinant, hybridoma and primary), applications of cell lines (R&D, biomanufacturing, diagnostics and cell therapy/regenerative medicine/tissue culture). In addition, the chapter includes information on additional cell line related services (bio-analytical/protein purification, cell banking, cell bank characterization, process development, GMP manufacturing and fill-finish), types of cell banks developed (master cell banks, working cell banks, research cell banks and end-of-production cell banks) and protein yield from cell lines. 
  • A company competitiveness analysis, highlighting prominent cell line development service providers based in different regions, taking into consideration their supplier strength (experience of the service provider), and portfolio specifications (sources of cell lines and expression systems handled, availability of proprietary/licensed technology platform, type of gene expression and availability of additional cell line related services).
  • Elaborate profiles of cell line development service providers. Each company profile features a brief overview of the company, its financial information (if available), cell line development and complementary services portfolio and an informed future outlook. 
  • A detailed review of the overall landscape of the cell line characterization services market, highlighting the contributions of industry and non-industry players along with the information on year of establishment, company size, location of headquarters, types of cells handled (mammalian, microbial, insect and others), types of cell line characterization services offered (identity/stability testing, sterility/biosafety testing, expression testing and oncogenicity/tumorigenicity testing), types of cell line identity/stability testing services offered (analysis of cell morphology, cytochrome c oxidase 1 barcoding assay, DNA fingerprinting/profiling, gene copy number analysis, isozyme analysis, karyotype analysis, nucleic acid sequencing, southern blotting and viability testing) types of sterility/biosafety testing services offered (mycoplasma contamination testing, microbial contamination testing, viral/adventitious agents contamination testing, retroviral contamination testing and rodent virus testing/in-vivo biosafety testing), availability of other cell line related services (cell line development, cell banking and mycoplasma clearance service), information on regulatory accreditations/certifications and overall turnaround time. In addition, it lists the non-industry players and provides information on number of STR loci amplified, type of genotyping kit used and service fee charged. 
  • A company competitiveness analysis, highlighting prominent cell line characterization service providers based in different regions, taking into consideration their supplier strength (experience of the service provider), and portfolio specifications (sources of cell lines and expression systems handled and size of the service portfolio.)
  • Elaborate profiles of cell line characterization service providers. Each company profile features a brief overview of the company, its financial information (if available), cell line characterization services portfolio and an informed future outlook.
  • A detailed analysis of the partnerships that have been established in the cell line development and characterization domain since 2015, covering technology platform utilization agreements, R&D collaborations, licensing agreements, mergers and acquisitions, product development and/or commercialization agreements, process development agreements, clinical trial agreements, and other relevant deals.
  • Detailed profiles of the biorepositories across the globe that play an important role in developing cell lines and have also undertaken initiatives to limit the use of contaminated and/or misidentified cell lines. Each profile features a brief overview of the repository and its cell line characterization service portfolio. 
  • An elaborate discussion on the requirements established by various regulatory authorities, across different regions, related to characterization of cell lines. In addition, it provides insights from the various guideline documents that have been issued by these bodies on protocols that need to be followed and general tips for the testing of cell lines. It also features a brief historical overview and discussion on the contributions of key institutes/organizations involved in this domain.
  • A survey analysis featuring inputs solicited from various experts who are directly/indirectly involved in providing cell line development and/or cell line characterization services.

One of the key objectives of the report was to estimate the existing market size and future growth opportunities for cell line development and characterization service providers. Based on multiple parameters, such as the number of projects completed annually, price of the projects, the overall R&D expenditure available to CROs and the overall growth of the biologics market, we have developed informed estimates on the financial evolution of the market over the period 2020-2030. 

For cell line development services market, our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] sources of cell lines and expression systems (mammalian, microbial, insect and avian), [B] applications of cell lines (R&D operations and drug development), [C] company size (small, mid-sized and large) and key geographies (North America, Europe, Asia, Oceania and Rest of the World).

For cell line characterization services market, our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] sources of cell lines and expression systems (mammalian, microbial and others), [B] applications of cell lines (R&D operations and drug development), [C] type of service provider (industry players and non-industry players) and [D] key geographies (North America, Europe, Asia, Middle East & North Africa (MENA), Latin America (LATAM) and Rest of the World (RoW)).
To account for the uncertainties associated with this industry and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. 

The report features detailed transcripts of interviews held with the following industry stakeholders (in reverse chronological order):


  • Fai Poon (Founder and President, Quacell Biotechnology)
  • Louis Boon (Chief Scientific Officer, Polpharma Biologics)
  • Fan Chen (Former Vice President BioProcessing, LakePharma)
  • Michael Pointek (Founder and Managing Director, ARTES Biotechnology) 
  • Nienke Smits (Client Relations Manager, Immunoprecise Antibodies)
  • Oscar Hoogteijling (Former Global Business Development Manager, Polpharma Biologics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered


  • Who are the leading players offering cell line development services?
  • What kind of CDMO support is available for cell line development, across different regions?
  • What are the common sources, gene delivery methods, protein yield and affiliated services offered by the cell line development service providers?
  • Who are the leading industry and non-industry players offering cell line characterization services?
  • What are the most popular services offered for characterization of cell lines?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • How is the current and future opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to cell line development and characterization market?

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Key Questions Answered
1.3. Research Methodology
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Cell Culture
3.2.1. Types of Cell Cultures by Origin
3.2.1.1. Primary Cell Cultures
3.2.1.2. Secondary Cell Cultures
3.2.2. Types of Cell Cultures by Growth Properties
3.2.2.1. Adherent Cell Cultures
3.2.2.2. Suspension Cell Cultures
3.2.3. Classification by Types of Cell Lines
3.2.3.1. Finite Cell Lines
3.2.3.2. Continuous Cell Lines
3.2.3.3. Recombinant Cell Lines
3.2.3.4. Hybridoma Cell Lines
3.3.4. Classification by Sources of Cell Lines
3.3.4.1. Mammalian Cell Lines
3.3.4.2. Non-Mammalian Cell Lines
3.5. Overview of Cell Line Development
3.5.1. Recombinant Cell Line Development
3.5.1.1. Vector Construction
3.5.1.2. Transgene Delivery into Host Cells
3.5.1.3. Cell Line Selection and Gene Amplification
3.5.1.4. Clone Selection
3.5.1.5. Stability Studies
3.6.2. Hybridoma Cell Line Development
3.7. Overview of Cell Line Characterization
3.7.1. Identity Testing
3.7.1.1. Karyotype Analysis
3.7.1.2. Isozyme Analysis
3.7.1.3. Cytochrome C Oxidase 1 Barcoding Assay
3.7.1.4. Phenotype Analysis
3.7.1.5. DNA Fingerprinting
3.7.1.6. DNA Profiling
3.8.2. Genetic Stability Testing
3.8.3. Sterility/Biosafety Testing
3..3.1. Mycoplasma Contamination Testing
3.6.3.2. Viral Contamination Testing
3.6.3.3. Other Sterility Testing Methods
3.7. Additional Cell Line Related Services
3.7.1. Cell Banking
3.7.1.1. Classification of Cell Banks
3.7.2. Process Development
3.7.2.1. Upstream Process Development
3.7.2.2. Downstream Process Development
3.7.3. cGMP Manufacturing
3.8. Applications of Cell Lines
3.9. Factors Affecting the Quality of Cell Lines
3.10. Need for Outsourcing Cell Line Related Operations

4. CELL LINE DEVELOPMENT SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Cell Line Development Service Providers: List of Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Source of Cell Line and Expression System Offered
4.2.5. Analysis by Types of Services Offered
4.2.5.1. Integrated Cell Line Characterization
4.2.5.2. Biosimilar Cell Line Development
4.2.5.3. Genetically Modified Cell Line Development
4.2.6. Analysis by Gene Delivery Method Used
4.2.7. Analysis by Type of Gene Expression
4.2.8. Analysis by Availability of Serum-Free/Animal Component Free Culturing Capabilities
4.2.9. Analysis by Types of Cell Cultures
4.2.10. Analysis by Types of Cells
4.2.11. Analysis by Applications of Cell Lines
4.2.12. Analysis by Availability of Additional Cell Line Related Services
4.2.13. Analysis by Type of Cell Bank(s) Developed
4.2.14. Geographical Presence Analysis of Companies (offering multiple cell lines) by Sources of Cell Lines and Company Size
4.2.14.1. North America
4.2.14.2. Europe
4.2.14.3. Asia-Pacific
4.2.15. Geographical Presence Analysis of Companies (offering a single cell line) by Source of Cell Line and Company Size
4.2.16. Heat Map Analysis: Analysis by Year of Establishment, Location of Headquarters and Additional Cell Line Related Services
4.2.17. Heat Map Analysis: Distribution by Location of Headquarters and Combinations of Sources of Cell Lines Offered
4.2.18. Information on Protein Yield from Cell Lines

5. CELL LINE DEVELOPMENT SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions/Key Parameters
5.3.1. Company Competitiveness Analysis: Cell Line Development Service Providers in North America
5.3.2. Company Competitiveness Analysis: Cell Line Development Service Providers in Europe
5.3.3. Company Competitiveness Analysis: Cell Line Development Service Providers in Asia-Pacific
5.4. Summary

6. COMPANY PROFILES: CELL LINE DEVELOPMENT SERVICE PROVIDERS
6.1. Chapter Overview
6.2. Cell Line Development Service Providers: North America
6.2.1. Creative Biogene
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Recent Developments and Future Outlook
6.2.2. Creative Biolabs
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Recent Developments and Future Outlook
6.2.3. Hyprocell
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Recent Developments and Future Outlook
6.2.4. LakePharma
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Recent Developments and Future Outlook
6.2.5. Thermo Fisher Scientific
6.2.5.1. Company Overview
6.2.5.2. Financial Information
6.2.5.3. Service Portfolio
6.2.5.4. Recent Developments and Future Outlook
6.3. Cell Line Development Service Providers: Europe
6.3.1. FUJIFILM Diosynth Biotechnologies
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Recent Developments and Future Outlook
6.3.2. Lonza
6.3.2.1. Company Overview
6.3.2.2. Financial Information
6.3.2.3. Service Portfolio
6.3.2.4. Recent Developments and Future Outlook
6.3.3. ProBioGen
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Recent Developments and Future Outlook
6.3.4. Polpharma Biologics
6.3.4.1. Company Overview
6.3.4.2. Service Portfolio
6.3.4.3. Recent Developments and Future Outlook
6.3.5. Selexis
6.3.5.1. Company Overview
6.3.5.2. Service Portfolio
6.3.5.3. Recent Developments and Future Outlook
6.4. Cell Line Development Service Providers: Asia-Pacific
6.4.1. Detai Bio-Tech
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Recent Developments and Future Outlook
6.4.2. WuXi Biologics
6.4.2.1. Company Overview
6.4.2.2. Financial Information
6.4.2.3. Service Portfolio
6.4.2.4. Recent Developments and Future Outlook

7. CELL LINE CHARACTERIZATION SERVICE PROVIDERS: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Cell Line Characterization Service Providers: Overall Market Landscape
7.2.1. Cell Line Characterization Service Providers: Industry Players
7.2.1.1. Analysis by Year of Establishment
7.2.1.2. Analysis by Company Size
7.2.1.3. Analysis by Location of Headquarters
7.2.1.4. Analysis by Types of Cells Handled
7.2.1.5. Analysis by Type of Cell Line Characterization Service(s) Offered
7.2.1.6. Analysis by Type of Cell Line Identity/Stability Testing Service(s) Offered
7.2.1.7. Analysis by Type of Sterility/Biosafety Testing Service(s) Offered
7.2.1.8. Analysis by Availability of Additional Cell Line Related Services
7.2.1.9. Geographical Presence Analysis of Companies (offering multiple cell lines) by Location of Headquarters
7.2.2. Cell Line Characterization Service Providers: Non-Industry Players
7.2.2.1. Analysis by Service Location
7.2.2.2. Analysis by Types of Cells Handled
7.2.2.3. Analysis by Type of Cell Line Characterization Service(s) Offered
7.2.2.4. Analysis by Number of STR Loci Amplified
7.2.2.5. Analysis by Type of Genotyping Kit(s) Used

8. CELL LINE CHARACTERIZATION SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Assumptions/Key Parameters
8.3.1. Company Competitiveness Analysis: Cell Line Characterization Service Providers in North America
8.3.2. Company Competitiveness Analysis: Cell Line Characterization Service Providers in Europe
8.3.3. Company Competitiveness Analysis: Cell Line Characterization Service Providers in Asia-Pacific
8.4. Summary

9. COMPANY PROFILES: CELL LINE CHARACTERIZATION SERVICE PROVIDERS
9.1. Chapter Overview
9.2. Cell Line Characterization Service Providers: North America
9.2.1. BioReliance
9.2.1.1. Company Overview
9.2.1.2. Service Portfolio
9.2.1.3. Recent Developments and Future Outlook
9.2.2. Charles River Laboratories
9.2.2.1. Company Overview
9.2.2.3. Financial Information
9.2.2.2. Service Portfolio
9.2.2.3. Recent Developments and Future Outlook
9.2.3. Molecular Diagnostic Services
9.2.3.1. Company Overview
9.2.3.2. Service Portfolio
9.2.3.3. Recent Developments and Future Outlook
9.3. Cell Line Characterization Service Providers: Europe
9.3.1. Eurofins BioPharma Product Testing
9.3.1.1. Company Overview
9.3.1.2. Service Portfolio
9.3.1.3. Recent Developments and Future Outlook
9.3.2. Sartorius Stedim Biotech
9.3.2.1. Company Overview
9.3.2.2. Financial Information
9.3.2.3. Service Portfolio
9.3.2.4. Recent Developments and Future Outlook
9.3.3. SGS
9.3.3.1. Company Overview
9.3.3.2. Service Portfolio
9.3.3.3. Recent Developments and Future Outlook
9.4. Cell Line Characterization Service Providers: Asia-Pacific
9.4.1. LivoGen Pharmed
9.4.1.1. Company Overview
9.4.1.2. Service Portfolio
9.4.1.3. Recent Developments and Future Outlook
9.4.2. TFBS Bioscience
9.4.2.1. Company Overview
9.4.2.2. Service Portfolio
9.4.2.3. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Cell Line Development and Characterization Service Providers: List of Partnerships and Collaborations
10.4. Analysis by Year of Partnership
10.5. Analysis by Type of Partnership
10.6. Analysis by Types of Cells Involved
10.7. Analysis by Type of Technology Platform Used
10.8. Analysis by Type of Indication
10.9. Analysis by Year of Partnership and Type of Partner
10.10. Analysis by Type of Partnership and Type of Partner
10.11. Most Active Players: Analysis by Number of Partnerships
10.12. Regional Analysis
10.13. Intercontinental and Intracontinental Agreements

11. CELL LINE REPOSITORIES
11.1. Chapter Overview
11.2. American Type Culture Collection (ATCC)
11.2.1. Overview
11.2.2. Service Portfolio
11.3. European Collection of Authenticated Cell Cultures (ECACC)
11.3.1. Overview
11.3.2. Service Portfolio
11.4. Leibniz Institute DSMZ
11.4.1. Overview
11.4.2. Service Portfolio
11.5. Coriell Institute for Medical Research
11.5.1. Overview
11.5.1.1. Service Portfolio

12. REGULATORY RECOMMENDATIONS AND GUIDELINES
12.1. Chapter Overview
12.2. History of Cell Line Authentication
12.3. Cell Line Authentication: Prominent Regulatory Authorities
12.3.1. Role of American Type Culture Collection (ATCC)
12.3.2. Role of International Cell Line Authentication Committee (ICLAC)
12.3.3. Role of Global Biological Standards Institute (GBSI)
12.4. Guidelines Issued by International Regulatory Agencies for Cell Line Characterization
12.4.1. World Health Organization (WHO)
12.4.2. The International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use
12.5. Regulatory Guidelines for Cell Line Characterization in the US
12.6. Regulatory Guidelines for Cell Line Characterization in Europe
12.7. Regulatory Guidelines for Cell Line Characterization in Japan

13. CELL LINE DEVELOPMENT SERVICES: MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Overall Cell Line Development Services Market, 2020-2030
13.4. Cell Line Development Services Market, 2020-2030: Distribution by Sources of Cell Lines and Expression Systems Used
13.5. Cell Line Development Services Market, 2020-2030: Distribution by Applications
13.6. Cell Line Development Services Market, 2020-2030: Distribution by Company Size
13.7. Cell Line Development Services Market, 2020-2030: Distribution by Geography
13.7.1. Cell Line Development Services Market in North America, 2020-2030
13.7.1.1. Cell Line Development Services Market in North America, 2020-2030: Share of Small-sized Companies
13.7.1.2. Cell Line Development Services Market in North America, 2020-2030: Share of Mid-sized Companies
13.7.1.3. Cell Line Development Services Market in North America, 2020-2030: Share of Large Companies
13.7.1.4. Cell Line Development Services Market in North America, 2020-2030: Share of Research and Development Operations
13.7.1.5. Cell Line Development Services Market in North America, 2020-2030: Share of Drug Development Operations
13.7.2. Cell Line Development Services Market in Europe, 2020-2030
13.7.2.1. Cell Line Development Services Market in Europe, 2020-2030: Share of Small-sized Companies
13.7.2.2. Cell Line Development Services Market in Europe, 2020-2030: Share of Mid-sized Companies
13.7.2.3. Cell Line Development Services Market in Europe, 2020-2030: Share of Large Companies
13.7.2.4. Cell Line Development Services Market in Europe, 2020-2030: Share of Research and Development Operations
13.7.2.5. Cell Line Development Services Market in Europe, 2020-2030: Share of Drug Development Operations
13.7.2. Cell Line Development Services Market in Asia, 2020-2030
13.7.2.1. Cell Line Development Services Market in Asia, 2020-2030: Share of Small-sized Companies
13.7.2.2. Cell Line Development Services Market in Asia, 2020-2030: Share of Mid-sized Companies
13.7.2.3. Cell Line Development Services Market in Asia, 2020-2030: Share of Large Companies
13.7.2.4. Cell Line Development Services Market in Asia, 2020-2030: Share of Research and Development Operations
13.7.2.5. Cell Line Development Services Market in Asia, 2020-2030: Share of Drug Development Operations
13.7.3. Cell Line Development Services Market in Oceania, 2020-2030
13.7.3.1. Cell Line Development Services Market in Oceania, 2020-2030: Share of Small-sized Companies
13.7.3.2. Cell Line Development Services Market in Oceania, 2020-2030: Share of Mid-sized Companies
13.7.3.3. Cell Line Development Services Market in Oceania, 2020-2030: Share of Large Companies
13.7.3.4. Cell Line Development Services Market in Oceania, 2020-2030: Share of Research and Development Operations
13.7.3.5. Cell Line Development Services Market in Oceania, 2020-2030: Share of Drug Development Operations
13.7.4. Cell Line Development Services Market in Rest of the World, 2020-2030
13.7.4.1. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Small-sized Companies
13.7.4.2. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Mid-sized Companies
13.7.4.3. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Large Companies
13.7.4.4. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Research and Development Operations
13.7.4.5. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Drug Development Operations

14. CELL LINE CHARACTERIZATION SERVICES: MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Forecast Methodology and Key Assumptions
14.3. Overall Cell Line Characterization Services Market, 2020-2030
14.4. Cell Line Characterization Services Market, 2020-2030: Distribution by Sources of Cell Lines
14.5. Cell Line Characterization Services Market, 2020-2030: Distribution by Geography
14.6. Cell Line Characterization Services Market, 2020-2030: Distribution by Type of Industry
14.7. Cell Line Characterization Services Market, 2020-2030: Distribution by Stage of Development of Biologics

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Northway Biotech
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Virgilijus Kupinas, Marketing and Business Development Coordinator (Q4 2020)
15.3. QuaCell Biotechnology
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Fai Poon, Founder and President (Q3 2020)
15.4. Polpharma Biologics
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Louis Boon, Chief Scientific Officer (Q3 2020)
15.5. LakePharma
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Fan Chen, Former Vice President BioProcessing (Q3 2017)
15.6. ARTES Biotechnology
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Michael Pointek, Founder and Managing Director (Q3 2017)
15.7. ImmunoPrecise Antibodies
15.7.1. Company Snapshot
15.7.2. Interview Transcript: Nienke Smits, Client Relations Manager (Q3 2017)
15.8. Bioceros (acquired by Polpharma Biologics)
15.8.1. Interview Transcript: Oscar Hoogteijling, Former Global Business Development Manager (Q3 2017)

16. SURVEY ANALYSIS
16.1. Chapter Overview
16.2. Overview of Respondents
16.3. Designation of Respondents
16.4. Survey Insights
16.4.1. Type of Cell Line Offered
16.4.2. Source of Cell Line
16.4.3. Applications of Cell Lines
16.4.4. Cell Line Characterization Services
16.4.5. Cell Banking Services
16.4.6. Biologics Manufacturing Services
16.4.7. Fill/Finish Services

17. CONCLUDING REMARKS
17.1. Chapter Overview
17.2. Key Takeaways

18. APPENDIX 1: TABULATED DATA19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 10x Genomics
  • 3P Biopharmaceuticals
  • 3SBio 
  • A&G Pharmaceutical 
  • Aarhus University Hospital 
  • AbbVie
  • Abcam
  • ABclonal
  • Abcuro
  • Abdi Ibrahim Pharmaceuticals
  • Abeomics
  • ABGENEX
  • ABL Bio
  • Abnova
  • AbSci
  • Abzena
  • AC Immune
  • AcceGen
  • Accelero Bioanalytics
  • Accuprec Research Labs
  • Accuratus Lab Services
  • Accurus Biosciences
  • ACE Biolabs
  • ACROBiosystems
  • Acticor Biotech
  • ACYTE Biotech
  • Adagene
  • AdaptVac
  • AddexBio Technologies
  • Advanced Biomart
  • Advaxis
  • Affinita Biotech
  • A-Frontier
  • AGC Biologics
  • Agenus
  • Airway Therapeutics
  • Akers Biosciences
  • Akshaya Bio
  • Albany Molecular Research (AMRI)
  • Albert Ludwigs University of Freiburg
  • Aldevron
  • Alligator Bioscience
  • Almirall
  • Alpha Lifetech
  • ALSTEM
  • Altogen Labs
  • Alvotech
  • America Pharma Source
  • Amicus Therapeutics
  • Ampersand Capital Partners
  • AMS Biotechnology (AMSBIO)
  • Analytical Biological Services (ABS)
  • Analytical Lab Group
  • Applied Biological Materials (abm)
  • Applied Genetics Laboratories (AGL)
  • APRINOIA Therapeutics
  • Aragen Bioscience
  • Aravive
  • ARETA International (ARETAINT)
  • Artelo Biosciences
  • ARTES Biotechnology
  • AscentGene
  • ASLAN Pharmaceuticals
  • Astellas Pharma
  • Asymchem
  • AtaGenix Laboratories
  • American Type Culture Collection (ATCC)
  • ATGCell
  • ATUM (formerly DNA2.0)
  • ATZ Labs
  • Augusta University
  • Australian Genome Research Facility (AGRF)
  • Austrianova
  • AutekBio
  • Avacta
  • Avance Biosciences
  • Avaxia Biologics
  • Avid Bioservices (formerly Peregrine Pharmaceuticals)
  • Axol Bioscience
  • Axon Scientific
  • Baliopharm
  • BaseClear
  • Batavia Biosciences
  • Bavarian Nordic
  • Bayer
  • Beckman Coulter
  • Beckman Research Institute of City of Hope
  • BeiGene
  • Berkeley Lights
  • Bex CO
  • Bhat Bio-tech India
  • BIBITEC
  • Bio Farma
  • Bioasis Technologies
  • BioAzure Technologies
  • Bioceros
  • BIO-ENGINEERING
  • BioFactura
  • Bioingenium
  • Biointron Biological
  • BioInvenu
  • BioLife Solutions
  • Biologics International
  • BioMax Lab
  • Bionique Testing Laboratories
  • Bionova Scientific
  • BioPharmaceuticals Australia (BPA)
  • BioReliance
  • Biosettia
  • Biosphere
  • BioSun Pharmed
  • Bio-Synthesis (BSI)
  • Biotechnology Hub Africa
  • BioTek Instruments
  • BioTickle
  • Biovian
  • BJ Bioscience
  • BLIRT (Biolab Innovative Research Technologies)
  • BMR Genomics
  • Boehringer Ingelheim Animal Health
  • Boehringer Ingelheim BioXcellence 
  • Boston Institute of Biotechnology
  • Boston Mountain Biotech
  • BPS Bioscience
  • BriaCell Therapeutics
  • Brii Biosciences
  • Bristol Myers Squibb
  • Broad Institute of MIT and Harvard
  • Brooks Automation
  • Bruker
  • Burnet Institute
  • C&M Biolabs
  • CALIXAR
  • CANbridge Pharmaceuticals
  • Canopy Biosciences
  • Capital Biosciences
  • Catalent Pharma Solutions
  • Cell and Genome Engineering Core, University of California
  • Cell Culture
  • Cell Guidance Systems
  • Cell Line Genetics
  • Cellaria
  • Cellca
  • Cellero
  • CellGenix
  • CellKraft Biotech
  • Cellomics Technology
  • CellSafe
  • Cells Online
  • Celltheon
  • Cellutron Life Technologies
  • CELONIC Group (formerly Glycotope Biotechnology)
  • Celplor
  • Celther Polska
  • Centre for Process Innovation (CPI)
  • Cerbios-Pharma
  • Ceva Santé Animale
  • CEVEC Pharmaceuticals
  • Changchun High & New Technology Industries Group
  • Charles River Laboratories
  • Children's Medical Research Institute
  • ChinaPeptides
  • Chiome Bioscience
  • ChristianaCare's Helen F. Graham Cancer Center & Research Institute 
  • Cipla Gulf
  • Clean Cells
  • Cleveland Clinic Lerner Research Institute
  • Clongen Laboratories
  • CLS Cell Lines Service
  • CMAB Biopharma
  • CMIC
  • Cobra Biologics
  • COBRE Grant Genomics, Biostatistics and Bioinformatics Core, Tulane    University
  • Codex DNA (formerly SGI-DNA)
  • Cognate BioServices 
  • Complix
  • Compugen
  • CORE Diagnostics
  • Cosmo Bio
  • Cosmogenetech
  • Covance
  • CPE
  • Creative Bioarray
  • Creative Biogene
  • Creative Biolabs
  • Creative BioMart
  • CSL
  • Curaxys
  • Cytovance Biologics
  • Cytiva
  • CZ Veterinaria
  • DC Biosciences
  • DC3 Therapeutics
  • DefiniGEN
  • Delphi Genetics
  • Denali Therapeutics
  • Detai Bio-Tech
  • Diagnostic Cytogenetics (DCI)
  • DiethelmKellerSiberHegner (DKSH)
  • DNA Diagnostics Center
  • DNA Forensics Laboratory
  • DPx Holdings 
  • Dr. KPC Life Sciences (formerly Chemgen Pharma)
  • Duke University School of Medicine
  • DYNAMIMED
  • Early Drug Development Group (E2DG)
  • Editas Medicine
  • EirGenix
  • Elabscience
  • Element Materials Technology
  • EMD Serono
  • EMP Genetech
  • Encure Biopharma
  • EPICS Therapeutics
  • EpiGex
  • ERS Genomics
  • Essen BioScience
  • Eton Bioscience
  • EuBiologics
  • EUGENEX Biotechnologies
  • EUPROTEIN
  • Eurofins BioPharma Product Testing
  • Eurofins DiscoverX
  • Eurofins Discovery
  • Eurofins Genomics
  • Eurofins Scientific 
  • Eurogentec
  • EuroscreenFAST
  • Eutilex
  • Evotec
  • Evox Therapeutics
  • Excelimmune
  • ExcellGene
  • exonbio
  • ExpreS2ion Biotechnologies
  • ExpressCells
  • Extherid Biosciences
  • Fapon Biotech
  • Faron Pharmaceuticals
  • Feinberg School of Medicine, Northwestern University
  • First BASE Laboratories
  • FlashCell
  • FlowMetric Life Sciences
  • Fountain Biopharma
  • Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB
  • Fred Hutchinson Cancer Research Center
  • French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 
  • Fuji Pharma
  • FUJIFILM Diosynth Biotechnologies
  • Fusion Antibodies
  • G&P Biosciences
  • G&W Biotechnologie 
  • Gemini Biosciences
  • Gene Center at Ludwig-Maximilians-Universität München
  • Genea Biocells
  • GeneBeyond
  • GeneCopoeia
  • Genedata
  • Genenmed (formerly Cancercide)
  • GENERI BIOTECH
  • Generium
  • Genetica DNA Laboratories 
  • GENEWIZ
  • Genexplore Diagnostics and Research Centre 
  • GenomeScan
  • Genovis
  • genOway
  • GenScript
  • GenScript ProBio
  • GenTarget
  • GeoVax Labs
  • German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)
  • German Collection of Microorganisms and Cell Cultures
  • GHO Capital Partners
  • GI Innovation
  • GlaxoSmithKline
  • GlycoBac
  • Glycotope
  • Goodwin Biotechnology
  • Pfizer- University of Granada- Junta de Andalucía Centre for Genomics and
  • Oncological Research (GENYO)
  • Grid Therapeutics
  • Griffith University
  • GT Biopharma
  • GTP Technology
  • GVK Biosciences (GVK BIO)
  • handyem
  • Haplogen Genomics
  • Harbour BioMed
  • Harvest Moon Pharmaceuticals
  • Heidelberg Pharma
  • Helsinki Institute of Life Science (HiLIFE)
  • HemaCare
  • Hepalink USA
  • Hera BioLabs
  • HistoCyte Laboratories
  • Hoba Therapeutics
  • Horizon Discovery
  • Humanigen
  • hylabs (Hy Laboratories)
  • Hyprocell
  • IBI - Istituto Biochimico Italiano Giovanni Lorenzini
  • IDEXX Laboratories
  • I-Mab Biopharma
  • ImmuneOncia Therapeutics
  • ImmuNext
  • ImmunoGenesis
  • ImmunoPrecise Antibodies
  • IMMUNOSTEP
  • Inhibrx
  • InSCREENeX
  • Institut für Forensische Genetik (IFG)
  • Integrated BioTherapeutics
  • IntelliCyt 
  • International AIDS Vaccine Initiative (IAVI)
  • Intervacc
  • InVivo BioTech Services
  • IRCCS San Martino Hospital – IST National Cancer Research Institute
  • JAMP Pharma
  • Janssen Biotech
  • The Jenner Institute, University of Oxford
  • JHL Biotech
  • Johns Hopkins University
  • JSR Life Sciences
  • Shanghai Junshi Biosciences 
  • Just Biotherapeutics
  • KBIO Health (Osong Advanced Medical Industry Promotion Foundation) 
  • KaryoLogic
  • KBI Biopharma
  • KEMP PROTEINS (formerly Kempbio)
  • KMD Bioscience
  • Korean Cell Line Bank
  • Krishgen Biosystems
  • KWR Water Research Institute
  • KYinno
  • Laboratorios Liomont
  • Laboratory Corporation of America Holdings (LabCorp)
  • LakePharma
  • Laragen
  • Laureate Biopharmaceutical Services
  • Lava Therapeutics
  • Legend Biotech
  • Leiden University Medical Centre (LUMC)
  • LFB Biomanufacturing
  • Life Technologies (India)
  • Limin International Group
  • Lipum
  • Livogen Pharmed
  • Lonza
  • Luminex
  • Lumosa Therapeutics
  • Mabion
  • MabPlex International
  • Mammoth Biosciences
  • MassBiologics
  • MaSTherCell Global
  • University of Texas MD Anderson Cancer Center 
  • Medvet Science
  • MeiraGTx
  • Memo Therapeutics
  • Memorial Sloan Kettering Cancer Center (MSK)
  • Merck
  • Merus
  • MGC Pharma (subsidiary of Mitsubishi Gas Chemical) 
  • Michigan State University  
  • Microbiology & Quality Associates
  • Microbiology Research Associates
  • Microsynth
  • Midas Pharma
  • MilliporeSigma (formerly Sigma-Aldrich)
  • Minapharm Pharmaceuticals 
  • Minerva Analytix
  • Mithra Biotechnology
  • MKS Instruments
  • ModiQuest Research (acquired by ImmunoPrecise)
  • Molecular Cloning Laboratories (MCLAB)
  • Molecular Diagnostic Services
  • Molecular Medicine (MolMed)
  • Momenta Pharmaceuticals
  • Moredun Scientific
  • Mount Sinai Health System
  • Multiplexion
  • Multispan
  • Mycenax Biotech
  • Mycoplasma Experience
  • Nashville Biosciences
  • National Biologics Facility
  • National Institute for Bioprocessing Research and Training (NIBRT)
  • Naturalis Biodiversity Center
  • Navrogen
  • NewLink Genetics
  • NGM Biopharmaceuticals
  • Noachis Terra
  • NorClone Biotech Laboratories
  • Nordmark Biotech
  • NorthGene
  • Northway Biotechpharma
  • Nouscom
  • Novasep
  • Novatein Biosciences
  • Nucleome Informatics
  • Oak BioSciences
  • Octapharma
  • Ogeda (formerly Euroscreen)
  • Okmed Biotech
  • Ology Bioservices (formerly Nanotherapeutics)
  • Oncologie
  • Oncotest
  • OneWorld Biotech
  • Oregon Health & Science University
  • OSE Immunotherapeutics
  • Oxford BioTherapeutics 
  • Oxford Expression Technologies (OET)
  • Oxford Genetics (OXGENE)
  • Oxford Nanopore Technologies (ONT)
  • PacificGMP
  • Pall Biotech
  • PanGen Biotech
  • Paragon Bioservices
  • Paraza Pharma
  • PATH
  • Patheon
  • PathoQuest
  • Pelican Therapeutics
  • Penn Purchasing Services, University of Pennsylvania 
  • Perfectus Biomed (formerly Extherid Biosciences)
  • Phanes Therapeutics
  • PharmAbcine
  • Pharmaron
  • PhaseBio Pharmaceuticals
  • Phylex BioSciences
  • Pieris Pharmaceuticals
  • Pionyr Immunotherapeutics (formerly Precision Immune)
  • Polpharma Biologics 
  • Polymun Scientific
  • Porton Biologics
  • Precision Antibody
  • Premas Biotech
  • Prestige Biopharma
  • Probiodrug
  • ProBioGen
  • Profacgen
  • Progenics Pharmaceuticals
  • Promega
  • PROMISE Proteomics 
  • Protein Technologies
  • ProteinCT Biotech
  • ProteoCell Biotechnologies
  • ProteoGenix
  • ProteoNic
  • PX'Therapeutics (formerly Protein'eXpert)
  • QED Bioscience
  • qGenomics
  • QIMR Berghofer Medical Research Institute
  • QuaCell Biotechnology
  • Queen’s University Belfast
  • Rajiv Gandhi Centre for Biotechnology
  • RD-Biotech
  • ReliaTech (Receptor Ligand Technologies)
  • Relief Therapeutics
  • Rentschler Biopharma
  • Richter-Helm BioLogics
  • Roche
  • Rockland Immunochemicals 
  • Rodon Biologics
  • Roswell Park Comprehensive Cancer Center
  • Rubicon Genomics
  • SAL Scientific
  • Samsung Biologics
  • Sandoz
  • Sanford Burnham Prebys Medical Discovery Institute
  • Sanofi
  • Sanyou Biopharmaceuticals
  • Sartorius Stedim BioOutsource
  • Sartorius Stedim Biotech
  • Sartorius Stedim Cellca
  • SB Drug Discovery
  • SecuGen 
  • Selecxine
  • Selexis
  • Serum Institute of India
  • SGS
  • Shanghai Biowing Applied Biotechnology 
  • Shanghai ChemPartner
  • Shanghai Medicilon
  • Shanghai Optima Biotechnology
  • Molecular Diagnostics Laboratory of Dana - Farber Cancer Institute 
  • Shenzhen Hepalink Pharmaceutical
  • Shire
  • Sigma-Aldrich
  • Signosis
  • Sinensis Life Sciences
  • Sino Biological
  • Six.02 Bioservices
  • Solentim
  • Sparta Systems
  • SPEED Biosystems
  • Sphere Fluidics
  • Spicona
  • STADA Arzneimittel
  • Statens Serum Institut
  • STC Biologics
  • STCube
  • Summit Pharmaceuticals International (SPI)
  • Sundia MediTech
  • Sunomix Biosciences
  • Surface Oncology
  • Svar Life Science (formerly Euro Diagnostica)
  • Swedish Orphan Biovitrum
  • SwissLumix
  • Syd Labs
  • Syngene International
  • Synovel Sciences
  • Synpromics 
  • System Biosciences
  • Takeda Pharmaceutical
  • TCG Lifesciences
  • tebu-bio
  • Technion Israel Institute of Technology
  • Teneobio
  • TentaMedix (formerly MicroMol)
  • Teva Pharmaceutical
  • Texcell
  • TFBS Bioscience
  • The Beatson Institute for Cancer Research, University of Glasgow
  • The Centre for Applied Genomics (TCAG)
  • The European Collection of Authenticated Cell Cultures (ECACC)
  • The Garvan Institute of Medical Research
  • The Helmholtz Protein Sample Production Facility (PSPF)
  • The Hospital for Sick Children (SickKids)
  • The Human Protein Atlas
  • The Microbial Type Culture Collection and Gene Bank (MTCC)
  • The Native Antigen Company
  • The Pirbright Institute
  • The State University of New York at Albany
  • The University of Manchester
  • The University of Sheffield
  • The University of Texas Medical Branch (UTMB)
  • The University of Vermont (UVM)
  • The Westmead Institute for Medical Research
  • The Wistar Institute
  • Therachon
  • Therapure Biopharma 
  • Thermo Fisher Scientific
  • Tizona Therapeutics
  • Toleranzia
  • TPG Biologics
  • Translational Research Platform for Veterinary Biologicals (TRPVB)
  • Transposagen Biopharmaceuticals
  • TransViragen
  • Trend Pharma & Tech
  • Trenzyme
  • TrueBinding (formerly Immutics)
  • Turgut Pharmaceuticals
  • TWIN HELIX
  • Twist Bioscience
  • Twist Bioscience
  • Ubiquigent
  • UC Berkeley DNA Sequencing Facility, University of California
  • UGA Biopharma
  • UNC School of Medicine
  • United BioLabs
  • United Biomedical (UBI)
  • United BioPharma (UBP)
  • University of Arizona
  • University of Cambridge
  • University of Colorado Anschutz Medical Campus
  • University of Connecticut
  • University of Edinburgh
  • University of Florida
  • University of Illinois
  • University of Maryland
  • University of Missouri
  • University of Pennsylvania
  • University of Pittsburgh
  • University of Sussex
  • University of Technology, Sydney
  • University of Utah 
  • University of Warsaw
  • University of Wisconsin School of Medicine and Public Health 
  • U-Protein Express
  • UT Southwestern Medical Center
  • Vaccine Research Institute (VRI) 
  • Vaccinex
  • Vaccitech
  • Valerius Biopharma
  • Vall d'Hebron Research Institute
  • Vectalys
  • VectorBuilder
  • Vectron Biosolutions
  • VelaLabs
  • Veterinary Medical Research & Development (VMRD)
  • Vibalogics
  • Vir Biotechnology
  • Virongy
  • ViruSure
  • Vista Biologicals
  • VTU Technology
  • VxP Biologics
  • Waisman Biomanufacturing
  • Washington University in St. Louis
  • WatsonBio Sciences
  • Wayne State University
  • Welgen
  • Wuhan Dian Biotechnology
  • WuXi Advanced Therapies
  • WuXi AppTec
  • WuXi Biologics
  • Wyndham Forensic Group
  • Xell
  • Xencor
  • Yale University
  • Zellkraftwerk
  • Zhejiang University 
  • Zumutor Biologics
  • Zymeworks
  • ZyVersa Therapeutics 

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

Biotechnology for the Non-Biotechnologist Training Course (December 2-6, 2024) - Product Image

Biotechnology for the Non-Biotechnologist Training Course (December 2-6, 2024)

  • Conference
  • 5 Days
  • Global
Cell Line Development Market Size and Forecasts 2020-2031: Global and Regional Share, Trends, and Growth Opportunity Analysis by Type, Application, and End-user - Product Image

Cell Line Development Market Size and Forecasts 2020-2031: Global and Regional Share, Trends, and Growth Opportunity Analysis by Type, Application, and End-user

  • Report
  • 117 Pages
  • Global
From
3D Cell Cultures: Technologies and Global Markets - Product Image

3D Cell Cultures: Technologies and Global Markets

  • Report
  • 442 Pages
  • Global
From
Collaboration Deals in Biotechnology 2019-2024 - Product Image

Collaboration Deals in Biotechnology 2019-2024

  • Report
  • 1200 Pages
  • Global
From
Cell Separation Market - Forecasts from 2023 to 2028 - Product Image

Cell Separation Market - Forecasts from 2023 to 2028

  • Report
  • 145 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.